Similar articles

• Methotrexate in juvenile idiopathic arthritis: answers and questions.

  Ravelli A, Martini A. Ravelli A, et al. J Rheumatol. 2000 Aug;27(8):1830-3. J Rheumatol. 2000. PMID: 10955319 No abstract available.
• [Juvenile rheumatoid arthritis].

  Honkanen V, Lahdenne P. Honkanen V, et al. Duodecim. 2000;116(8):839-43. Duodecim. 2000. PMID: 11787127 Review. Finnish. No abstract available.
• Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

  Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, Henrickson M, Watcher S, Reiff A. Kimura Y, et al. J Rheumatol. 2005 May;32(5):935-42. J Rheumatol. 2005. PMID: 15868633
• Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.

  Behrens F, Koehm M, Burkhardt H. Behrens F, et al. Curr Opin Rheumatol. 2011 May;23(3):282-7. doi: 10.1097/BOR.0b013e328344fddb. Curr Opin Rheumatol. 2011. PMID: 21427581 Review.
• Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy.

  Gadadhar H, Hawkins S, Huffstutter JE, Panda M. Gadadhar H, et al. J Clin Rheumatol. 2007 Dec;13(6):361-2. doi: 10.1097/RHU.0b013e31815d3ddd. J Clin Rheumatol. 2007. PMID: 18176152 No abstract available.